Pfizer Inc. (NYSE:PFE) is one of the
7 Best Longevity Stocks to Buy Now.
On June 8, 2026, Pfizer Inc. (NYSE:PFE) announced that the U.S. FDA approved an expanded indication for Hympavzi to include patients with hemophilia A or B 12 years and older with inhibitors and pediatric patients with or without inhibitors. Hympavzi is now indicated in the U.S. for routine prophylaxis to prevent or reduce bleeding episodes in adults and pediatric patients 6 years and older with hemophilia A with or without factor VIII inhibitors, or hemophilia B with or without factor IX inhibitors.
On June 7, 2026, Pfizer Inc. (NYSE:PFE) presented detailed Phase 2b results for berobenatide, an investigational monthly GLP-1 receptor agonist peptide, at the 86th Scientific Sessions of the American Diabetes **** ociation. The company said the VESPER-1, 2, and 3 studies provided proof of concept for berobenatide as a potential first-in-class monthly GLP-1 RA peptide, showed favorable tolerability, and highlighted potential advantages from monthly delivery and a 0.5 mL injection volume.
On May 31, 2026, Pfizer Inc. (NYSE:PFE) announced detailed progression-free and overall survival results from Cohort 3 of the Phase 3 Breakwater trial. Pfizer said median progression-free survival was nearly doubled with the BRAFTOVI combination regimen versus the comparator.
7 Best Longevity Stocks to Buy Now.
On June 8, 2026, Pfizer Inc. (NYSE:PFE) announced that the U.S. FDA approved an expanded indication for Hympavzi to include patients with hemophilia A or B 12 years and older with inhibitors and pediatric patients with or without inhibitors. Hympavzi is now indicated in the U.S. for routine prophylaxis to prevent or reduce bleeding episodes in adults and pediatric patients 6 years and older with hemophilia A with or without factor VIII inhibitors, or hemophilia B with or without factor IX inhibitors.
On June 7, 2026, Pfizer Inc. (NYSE:PFE) presented detailed Phase 2b results for berobenatide, an investigational monthly GLP-1 receptor agonist peptide, at the 86th Scientific Sessions of the American Diabetes **** ociation. The company said the VESPER-1, 2, and 3 studies provided proof of concept for berobenatide as a potential first-in-class monthly GLP-1 RA peptide, showed favorable tolerability, and highlighted potential advantages from monthly delivery and a 0.5 mL injection volume.
On May 31, 2026, Pfizer Inc. (NYSE:PFE) announced detailed progression-free and overall survival results from Cohort 3 of the Phase 3 Breakwater trial. Pfizer said median progression-free survival was nearly doubled with the BRAFTOVI combination regimen versus the comparator.
5 months ago
